American heart journal plus : cardiology research and practice最新文献

{"title":"Changes in health insurance status and mortality in patients with acute heart failure","authors":"Federico Viganego ,&nbsp;Mark K. Meiselbach ,&nbsp;Michael G. Fradley ,&nbsp;Samer S. Najjar","doi":"10.1016/j.ahjo.2025.100567","DOIUrl":"10.1016/j.ahjo.2025.100567","url":null,"abstract":"<div><h3>Introduction</h3><div>Health insurance changes (HIC) can lead to coverage gaps, alter the continuity of care, potentially affecting clinical outcomes; Heart Failure (HF) is a leading contributor to hospital readmissions in the U.S. We analyzed the relationship between HIC, readmission costs and mortality in patients with HF after a recent hospitalization.</div></div><div><h3>Methods</h3><div>We used data from the 2019 National Readmission Database to analyze 30-day re-admission incidence, costs and mortality in hospitalized HF patients in relation to HIC.</div></div><div><h3>Results</h3><div>Among 569,714 acute HF admissions, 4.2 % of patients (<em>n</em> = 4811) experienced HIC within 30 days; HIC were associated with younger age, more comorbidities, and Medicaid coverage. HIC were associated with higher readmission mortality, longer hospitalizations and increased hospital costs.</div></div><div><h3>Conclusion</h3><div>HIC in high-risk HF patients are associated with worse clinical outcomes and higher cost burden, highlighting the need for efforts aimed at preserving continuity of coverage in this population.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"56 ","pages":"Article 100567"},"PeriodicalIF":1.3,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144338221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insights from one American Indian tribe about heart health","authors":"Sarah de Loizaga ,&nbsp;McCall Miller ,&nbsp;Barbie Giambra ,&nbsp;LeCario Benashley ,&nbsp;Billie Bones ,&nbsp;Samantha Buonfiglio ,&nbsp;Gwendena Lee Gatewood ,&nbsp;Amanda Paxson ,&nbsp;Teresa Pestian ,&nbsp;Rachel Sarnacki ,&nbsp;Rhiannon Walker ,&nbsp;Dawnafe Whitesinger ,&nbsp;Andrea Beaton ,&nbsp;Lisa M. Vaughn","doi":"10.1016/j.ahjo.2025.100564","DOIUrl":"10.1016/j.ahjo.2025.100564","url":null,"abstract":"<div><h3>Background</h3><div>American Indians are impacted by significant health disparities compared to the general US population, with cardiovascular disease as a leading cause of death. Additionally, many American Indian populations face significant barriers to accessing specialty cardiac care. For one American Indian Tribe in Eastern Arizona, barriers to care include long distances to travel for echocardiography or cardiology consultation and delays in diagnosis. The purpose of this study was to gain insight into tribal perspectives of heart health and priorities in the design of a hearthealth program.</div></div><div><h3>Methods</h3><div>We used qualitative semi-structured interviews to examine Tribal experiences and perspectives surrounding heart health and health in general on Tribal lands. The Community Research Leadership Board assisted with developing the interview guide, recruitment, and data collection.</div></div><div><h3>Results</h3><div>A total of 19 interviews were completed. We used thematic analysis and identified five primary themes: 1) Awareness leads to understanding and acceptance; 2) Systemic barriers impede heart-health care; 3) Community engagement supports a sustainable heart-health program; 4) Heart-health initiatives can be influenced by personal perspectives; and 5) Expanded resources enable engagement.</div></div><div><h3>Conclusion</h3><div>Improvement in heart-health care and management is urgently needed for American Indian peoples who are disproportionately impacted by poor heart outcomes. Our findings suggest that a heart-health initiative for this Tribe needs to raise community awareness, address individual and systemic barriers, and leverage community strengths. These findings will directly inform planned persona development and community-based design workshops as we work toward a co-developed, impactful, and sustainable heart-health program.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"56 ","pages":"Article 100564"},"PeriodicalIF":1.3,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144271528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early diagnosis of acute myocardial infarction via hub genes identified by integrated weighted gene co-expression network analysis","authors":"Kun Huang ,&nbsp;Feng Wen ,&nbsp;Jingyi Li ,&nbsp;Wenhao Niu ,&nbsp;Hui Chen ,&nbsp;Shilei Wan ,&nbsp;Fupeng Yang ,&nbsp;Yihong Chen ,&nbsp;Chun Liang","doi":"10.1016/j.ahjo.2025.100554","DOIUrl":"10.1016/j.ahjo.2025.100554","url":null,"abstract":"<div><h3>Background</h3><div>Acute myocardial infarction (AMI) is a leading cause of morbidity and mortality worldwide. Circulating endothelial cells (CECs) have been reported to be involved with the early stages of AMI. The specific objective of our study was to discover early diagnostic markers of CECs in circulation using bioinformatics analysis.</div></div><div><h3>Methods</h3><div>Raw microarray data of the GSE66360 dataset were acquired from the Gene Expression Omnibus (GEO) database. The R software was used to filtrate differentially expressed genes (DEGs) from the discovery cohort of GSE66360 (<em>n</em> = 43). A weighted gene co-expression network analysis (WGCNA) was performed to explore the key modules connected with AMI. Next, main roles of the pathological states in AMI were analyzed using GO and KEGG and PPI networks. Diagnostic biomarkers were selected and identified using three machine learning algorithms. Additionally, the expression and diagnostic efficiency of hub genes were verified in the validation cohort (<em>n</em> = 56).</div></div><div><h3>Results</h3><div>366 DEGs were identified (20 upregulated and 306 downregulated). A total of 276 intersecting genes were markedly associated with AMI in the pink and turquoise modules. Based on multiple machine learning algorithms and independent validation, six genes including LILRA1, CCL20, IL1R2, TYROBP, CXCL16 and NFKBIA were identified as hub genes and showed satisfactory diagnostic efficiency both in the discovery cohort and validation cohort.</div></div><div><h3>Conclusion</h3><div>Our data provides evidence supporting a list of six hub genes to be trapped in the pathophysiology of AMI and proposes them as candidate biomarkers for the early diagnosis of AMI.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"56 ","pages":"Article 100554"},"PeriodicalIF":1.3,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144262671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of aortic valve calcification volume on left ventricular systolic function in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation","authors":"Helen S. Anwar ,&nbsp;Magdy Algowhary ,&nbsp;Mohamed Aboel-Kassem F. Abdelmegid ,&nbsp;Hatem A. Helmy ,&nbsp;J.M. Montero-Cabezas ,&nbsp;Frank Van Der Kley","doi":"10.1016/j.ahjo.2025.100562","DOIUrl":"10.1016/j.ahjo.2025.100562","url":null,"abstract":"<div><h3>Background</h3><div>Aortic valve calcification (AVC) has been linked to negative cardiac outcomes in patients with aortic stenosis (AS). Given the limited understanding of its specific contributions, we aimed to investigate the interaction between AVC and the left ventricular (LV) systolic function in patients with severe AS and LV systolic dysfunction who underwent transcatheter aortic valve implantation (TAVI).</div></div><div><h3>Materials and methods</h3><div>An observational study of 75 patients with severe AS and LV ejection fraction (EF) ≤ 50 % who underwent TAVI. AVC volume was determined by ECG-gated contrast-enhanced multidetector computed tomography (MDCT) using specific software (3Mensio Structural Heart version 10.4, Pie Medical Imaging, Maastricht, the Netherlands). Patients were categorized into two groups based on LV systolic function recovery 30 days after TAVI defined by ≥10 % absolute increase in LVEF compared to baseline.</div></div><div><h3>Results</h3><div>AVC volume showed a statistically significant negative correlation with the baseline LVEF (<em>r</em> = −0.33, <em>P</em> = 0.008) and a statistically significant positive correlation with the percentage of change in LVEF as compared to the baseline (<em>r</em> = 0.38, <em>P</em> = 0.001). In the logistic regression for post-TAVI LV systolic function recovery, AVC volume was associated with an increased likelihood of LV systolic function recovery.</div></div><div><h3>Conclusion</h3><div>AVC volume has a paradoxical association with LV systolic function. Patients with a higher AVC volume had a more depressed baseline LV systolic function and a greater likelihood of LV systolic function recovery after TAVI.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"56 ","pages":"Article 100562"},"PeriodicalIF":1.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144213506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-invasive mapping of ventricular action potential waveforms reconstructed from clinical unshielded magnetocardiography. Potential diagnostic application and current limitations","authors":"Riccardo Fenici ,&nbsp;Marco Picerni ,&nbsp;Peter Fenici ,&nbsp;Donatella Brisinda","doi":"10.1016/j.ahjo.2025.100561","DOIUrl":"10.1016/j.ahjo.2025.100561","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the feasibility and limitations of reconstructing ventricular action potential waveforms using non-invasive, unshielded magnetocardiographic mapping (uMCG), highlighting differences between healthy individuals and patients, even at the current level of precision.</div></div><div><h3>Methods</h3><div>Clinical uMCG was performed using a 36-channel DC-SQUID system. The mathematical reconstruction method developed by Kandori et al. was applied to derive reconstructed ventricular action potential waveforms (rVAPw) from uMCG data in 10 healthy volunteers and 12 patients with various cardiac abnormalities. In four cases, simultaneous recordings of uMCG and right ventricular monophasic action potentials (RVMAP) were obtained using an amagnetic catheter technique.</div></div><div><h3>Results</h3><div>Reconstruction of rVAPw from uMCG signals was feasible in all subjects. Waveforms derived from 90-s averaged uMCG signals were comparable to those obtained with 300-s averages. The rVAPw closely matched the simultaneously recorded RVMAP waveforms. Compared to healthy individuals, patients showed a significant prolongation of rVAPw phase-0 (p &lt; 0.01) and a trend toward increased total duration (p = 0.06), demonstrating the method's sensitivity to electrophysiological abnormalities.</div></div><div><h3>Conclusions</h3><div>While incomplete rVAPw at some MCG mapping sites reflects the current spatial resolution limitations of the uMCG array, the close alignment between rVAPw and RVMAP recordings suggests that 90-s uMCG acquisitions may suffice for reliable, non-invasive imaging of ventricular action potentials in clinical practice. These findings support further development of MCG technology as a medical device uniquely suited to bridge experimental and clinical applications by enabling non-invasive rVAPw mapping in patients. Future improvements in sensor technology, mathematical modelling, and multimodal imaging may allow for near-cellular spatial resolution.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"55 ","pages":"Article 100561"},"PeriodicalIF":1.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144204253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a) and coronary artery disease: The need for universal screening – A case-based review","authors":"Nguyen Yen Nhi Ngo,&nbsp;Chloé Davidson Villavaso,&nbsp;Chisom Joan Orakwue,&nbsp;William Zachary Rowalt,&nbsp;Madhur Roberts,&nbsp;Keith C. Ferdinand","doi":"10.1016/j.ahjo.2025.100560","DOIUrl":"10.1016/j.ahjo.2025.100560","url":null,"abstract":"<div><h3>Introduction</h3><div>Atherosclerosis cardiovascular disease (ASCVD), especially coronary artery disease (CAD), remains the leading cause of death worldwide, with several well-identified risk factors. This case report presents a premenopausal female with low calculated ASCVD risk, hypertension, elevated lipoprotein(a) [Lp(a)], and clinically significant CAD.</div></div><div><h3>Case report</h3><div>A 44-year-old premenopausal White female with controlled stage 2 hypertension, and overall low calculated 10-year ASCVD risk, was found to have severe CAD. She presented to the clinic with worsening chest discomfort during exertion and was diagnosed with a heavily calcified proximal left anterior descending artery stenosis, necessitating percutaneous coronary intervention.</div></div><div><h3>Discussion</h3><div>The global prevalence of elevated Lp(a) &gt;50 mg/dL is around 1.43 billion. Elevated lipoprotein(a) is now recognized, based on the preponderance of the evidence, by several international scientific statements as an independent risk factor for ASCVD, including CAD. Nevertheless, the current 2018 American College of Cardiology (ACC) and American Heart Association (AHA) multi-society guideline on the Management of Blood Cholesterol only classifies Lp(a) as a risk enhancer. This recommendation, along with the lack of approved pharmacotherapy has contributed to limited testing in current United States clinical practice (&lt;1 % for the general population). Furthermore, the inadequate assessment of Lp(a) may lead to an underestimation of ASCVD risk.</div></div><div><h3>Conclusion</h3><div>This case highlights the shortcomings of inadequate assessment of Lp(a) leading to the underestimation of cardiovascular risk. Accordingly, with multiple recent international scientific statements, clinicians should universally screen for elevated Lp(a). In the future, investigational therapies for lowering Lp(a) may be crucial for improving patient outcomes.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"56 ","pages":"Article 100560"},"PeriodicalIF":1.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating risk factors of embolism in patients with cardiac myxoma: A systematic review and meta-analysis","authors":"Muhammad Ahmad Qureshi ,&nbsp;Danyal Bakht ,&nbsp;Omair Ahmed ,&nbsp;Shahan Haseeb ,&nbsp;Kartik Gupta ,&nbsp;Omar Baqal ,&nbsp;Maaz Amir ,&nbsp;Khawar Ali ,&nbsp;Mirza Muhammad Hadeed Khawar ,&nbsp;Muqaddas Hussain ,&nbsp;Luqman Munir ,&nbsp;Hussein Othman","doi":"10.1016/j.ahjo.2025.100559","DOIUrl":"10.1016/j.ahjo.2025.100559","url":null,"abstract":"<div><h3>Background</h3><div>Cardiac myxomas (CM), the most common primary cardiac tumors, can cause embolism in about 40 % of cases, making it crucial to identify risk factors for guiding clinical decisions.</div></div><div><h3>Objectives</h3><div>In this meta-analysis, we studied the risk factors associated with embolism among patients with cardiac myxomas.</div></div><div><h3>Methods</h3><div>A comprehensive search was conducted across PubMed, Embase, and Cochrane Library from their inception until May 2023. Statistical analyses were performed using Cochrane's RevMan 5.4 software. For each risk factor, the pooled odds ratio or mean difference was calculated along with the corresponding 95 % confidence interval.</div></div><div><h3>Results</h3><div>This meta-analysis incorporated 18 studies with 2601 patients, of whom 525 (20.1 %) experienced embolism. Significant risk factors included hypertension (<em>p</em> = 0.001), NYHA I/II (<em>p</em> = 0.03), irregular tumor surface (<em>p</em> &lt; 0.01), hyperlipidemia (p &lt; 0.01), coronary artery disease (<em>p</em> = 0.01), elevated mean platelet volume (<em>p</em> = 0.02), and high tumor mobility (p &lt; 0.01), while female gender (p = 0.03) was linked to reduced risk. Smoking, atrial fibrillation, tumor size, age, BMI, diabetes, LVEF, and LAD were not significantly associated with embolism (<em>p</em> &gt; 0.05).</div></div><div><h3>Conclusion</h3><div>This analysis is the first to highlight significant pooled outcomes for gender, hyperlipidemia, coronary artery disease, mean platelet volume, and tumor mobility. Patients with these risk factors may benefit from early evaluation and surgery to reduce embolism risk. Statistical analyses were performed using RevMan 5.4, with pooled odds ratios or mean differences calculated alongside 95 % confidence intervals.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"56 ","pages":"Article 100559"},"PeriodicalIF":1.3,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144253628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential role of gut microbiota in cardiac arrhythmias","authors":"Ramil Goel ,&nbsp;Gurjit Singh ,&nbsp;Carl J. Pepine","doi":"10.1016/j.ahjo.2025.100557","DOIUrl":"10.1016/j.ahjo.2025.100557","url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"55 ","pages":"Article 100557"},"PeriodicalIF":1.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supersaturated oxygen therapy using radial artery access to prevent left ventricular remodeling after anterior ST-segment elevation myocardial infarction: a randomized, controlled trial","authors":"Francis R. Joshi ,&nbsp;Maria Petty ,&nbsp;Yen Wing Ng ,&nbsp;Hamish Elliott ,&nbsp;Ross Anderson ,&nbsp;Douglas Gordon ,&nbsp;Rebecca Hanna ,&nbsp;Robert Sykes ,&nbsp;Shaun Leonard ,&nbsp;Andrew Morrow ,&nbsp;Dylan Tan ,&nbsp;Anna Kamdar ,&nbsp;Ramu Perumal ,&nbsp;Jeffrey L. Creech ,&nbsp;Peter Kellman ,&nbsp;Paul Welsh ,&nbsp;Alex McConnachie ,&nbsp;Colin Berry","doi":"10.1016/j.ahjo.2025.100556","DOIUrl":"10.1016/j.ahjo.2025.100556","url":null,"abstract":"<div><h3>Background</h3><div>Novel strategies to limit the size of infarction and prevent adverse remodeling and heart failure in patients following acute ST-segment elevation myocardial infarction (STEMI) are lacking. Supersaturated oxygen (SSO₂) therapy is approved for patients presenting within 6 h of onset of anterior STEMI using femoral artery access. The feasibility of SSO₂ therapy via radial access is unknown. A more detailed understanding of the effect of therapy is needed.</div></div><div><h3>Objectives</h3><div>To assess the primary outcome, defined as the within-participant change in the plasma concentration of NT-proBNP measured at baseline, 24 h, 2–5 days and 3-months post-MI.</div></div><div><h3>Design</h3><div>Prospective, randomized, controlled, blinded, endpoint (mechanistic, PROBE) clinical trial.</div></div><div><h3>Randomized, controlled trial</h3><div>After primary PCI, eligible participants will be blinded and randomized 2:1 to either 1 h of SSO₂ therapy using radial artery access and intravenous glycoprotein IIbIIIa inhibitor therapy or a control (sham) procedure involving wrist manipulation in addition to standard care. The primary outcome is the within-participant change in the plasma concentration of NT-proBNP as detailed above. Secondary outcome assessments include coronary microcirculatory function, infarct size, microvascular obstruction, myocardial hemorrhage, left ventricular remodeling, myocardial blood flow, quality of life (EQ-5D-5L), Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Duke Activity Status Index. Patient reported experience measures (PREMS) are an exploratory outcome. Health and economic outcomes will be assessed using electronic healthcare records.</div></div><div><h3>Value</h3><div>The study will test the feasibility of radial artery access, provide mechanistic data and inform a larger multicenter trial powered to detect treatment effects on clinical endpoints.</div><div><span><span>Clinicaltrials.gov</span><svg><path></path></svg></span>: <span><span>NCT06662890</span><svg><path></path></svg></span></div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"55 ","pages":"Article 100556"},"PeriodicalIF":1.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144178326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GLP-1 receptor agonists and pulmonary hypertension in diabetes: A promising therapeutic strategy","authors":"Arif Albulushi ,&nbsp;Khaled El-Sharnouby ,&nbsp;Kareem Soror ,&nbsp;Noora Alhajri ,&nbsp;Giuseppe Imperator","doi":"10.1016/j.ahjo.2025.100555","DOIUrl":"10.1016/j.ahjo.2025.100555","url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary hypertension (PH) is an emerging and underrecognized complication of diabetes mellitus, linked to adverse cardiopulmonary outcomes. Insulin resistance, inflammation, and endothelial dysfunction contribute to PH pathogenesis.</div></div><div><h3>Objective</h3><div>This review evaluates the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in mitigating PH risk among diabetic patients.</div></div><div><h3>Methods</h3><div>We synthesized data from preclinical and clinical studies, including large-scale observational cohorts, investigating GLP-1RAs' effects on pulmonary vasculature and hemodynamics.</div></div><div><h3>Results</h3><div>GLP-1RAs exhibit anti-inflammatory, vasodilatory, and endothelial-protective properties, with associated improvements in pulmonary artery pressure, vascular remodeling, and cardiopulmonary load. A Veterans Affairs cohort and meta-analyses suggest a reduced PH incidence among GLP-1RA users.</div></div><div><h3>Conclusion</h3><div>GLP-1RAs may represent a novel cardiopulmonary intervention in diabetes care. Prospective trials are needed to confirm their protective role against PH and define optimal integration into therapeutic strategies.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"55 ","pages":"Article 100555"},"PeriodicalIF":1.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}